Bonprove Ibandronic Acid 150 Mg 3 Tablets

Bonprove Ibandronic Acid 150 Mg 3 Tablets

Description:

Bonprove Ibandronic Acid 150 mg 3 Tablets is a prescription oral bisphosphonate medicine used for the treatment and prevention of osteoporosis in adults, particularly postmenopausal women at increased risk of fractures. Each film-coated tablet contains 150 mg of ibandronic acid, a potent inhibitor of bone resorption that helps increase bone mineral density and reduce the risk of vertebral fractures. Bonprove is designed for convenient once-monthly dosing, supporting long-term bone health and fracture prevention when used under medical supervision alongside adequate calcium and vitamin d intake.

Indications:

• Treatment of osteoporosis in postmenopausal women to reduce the risk of vertebral fractures.
• Prevention of osteoporosis progression in adults with low bone mineral density as assessed by a healthcare professional.
• Management of osteoporosis in adults at high risk of fracture (e.g., history of osteoporotic fracture, long-term corticosteroid use) as prescribed by a doctor.
• Support of bone strength and reduction of excessive bone loss associated with postmenopausal estrogen deficiency.

Active Ingredients / Key Components:

• Ibandronic acid – 150 mg per film-coated tablet.
• Excipients: The full list of inactive ingredients (tablet core and film-coating components such as fillers, binders, colorants, and stabilizers) is not available in the provided information. Please refer to the official package leaflet for the complete excipient list.

Dosage & Administration / How to Use:

• Recommended dose for adults: one film-coated tablet containing 150 mg ibandronic acid taken once monthly on the same date each month, or exactly as prescribed by your doctor.
• Take the tablet first thing in the morning after an overnight fast, at least 6 hours after any food or drink other than plain water.
• Swallow the tablet whole with a full glass of plain water (approximately 200 ml). Do not chew, suck, or crush the tablet.
• After taking the tablet, remain in an upright position (sitting or standing) for at least 60 minutes. Do not lie down during this period.
• Do not eat, drink (other than plain water), or take any other oral medicines, calcium supplements, antacids, or vitamins for at least 60 minutes after taking Bonprove, as these can reduce absorption.
• If a dose is missed and the next scheduled dose is more than 7 days away, take one tablet the morning after you remember, then return to your original monthly schedule. If the next dose is within 7 days, skip the missed tablet and continue with your regular date. Do not take two tablets within the same week.
• Use only under medical supervision. Duration of therapy is determined by your doctor based on your bone mineral density, fracture risk, and clinical response.

Clinical Benefits:

• Helps increase bone mineral density by inhibiting excessive bone resorption and supporting stronger bones.
• Reduces the risk of vertebral fractures in postmenopausal women with osteoporosis when used regularly as prescribed.
• Provides convenient once-monthly dosing, which may improve adherence compared with more frequent bisphosphonate regimens.
• Supports long-term management of osteoporosis when combined with adequate calcium and vitamin d intake and lifestyle measures such as weight-bearing exercise.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to ibandronic acid or any of the excipients.
• Contraindicated in patients with abnormalities of the esophagus that delay esophageal emptying (e.g., stricture, achalasia) or in those who cannot stand or sit upright for at least 60 minutes.
• Use with caution in patients with severe renal impairment; dose adjustment or alternative therapy may be required as determined by a physician.
• Ensure adequate calcium and vitamin d intake during treatment; correct any pre-existing hypocalcemia or other disturbances of bone and mineral metabolism before starting therapy.
• Cases of upper gastrointestinal irritation, esophagitis, and ulcers have been reported with bisphosphonates. Follow administration instructions carefully to reduce this risk.
• Osteonecrosis of the jaw has been reported rarely, especially in patients with cancer receiving intravenous bisphosphonates, invasive dental procedures, or poor oral hygiene. Inform your dentist that you are taking a bisphosphonate and maintain good oral care.
• Consult your doctor before use if you are pregnant, planning pregnancy, or breastfeeding. Ibandronic acid is generally not recommended during pregnancy or lactation unless clearly needed and prescribed by a physician.
• Consult your doctor before use if you have kidney disease, gastrointestinal disorders (such as gastritis, ulcers, Barrett’s esophagus), vitamin d deficiency, or problems with swallowing.
• Do not use in children or adolescents; safety and efficacy in pediatric patients have not been established.
• Keep out of reach of children.

Side Effects:

• Common side effects may include gastrointestinal symptoms such as abdominal pain, dyspepsia, nausea, diarrhea, or constipation, as well as headache or flu-like symptoms (muscle pain, joint pain, fever) particularly after the first dose.
• Less common side effects may include esophagitis, esophageal irritation, gastritis, or ulcers, especially if dosing instructions are not followed correctly.
• Rare but serious side effects can include severe allergic reactions (rash, swelling of face/lips/tongue, difficulty breathing), osteonecrosis of the jaw, atypical femoral fractures, or severe bone, joint, or muscle pain.
• Stop taking the medicine and seek immediate medical attention if you experience chest pain, new or worsening difficulty swallowing, painful swallowing, severe heartburn, or severe allergic reactions.
• Report any persistent thigh, hip, or groin pain to your doctor, as this could be an early sign of an atypical femoral fracture.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.

Specifications:

• Serving size: 1 film-coated tablet (150 mg ibandronic acid).
• Count: 3 film-coated tablets per pack.
• Form: Oral tablet (film-coated).
• Intended use: Prescription medicine for osteoporosis management in adults as directed by a healthcare professional.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.